Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of June 2026
Principal Executive Office: Level 15, 500 Collins Street, Melbourne, Victoria 3000 Australia
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. As a development stage enterprise, the document focuses on corporate governance updates rather than financial performance data.
Material Changes
The primary material change disclosed in this filing is a Change of Director's Interest, submitted as Exhibit 99.1. No financial material changes are reported in this specific document.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, outlook, or specific risk factors. The document serves primarily to incorporate the Change of Director's Interest Notice into existing Registration Statements on Form S-8 and Form F-3.
Investor Verification Checklist
- Verify the specific details of the Director's interest change in Exhibit 99.1.
- Confirm the status of the referenced Registration Statements (Form S-8 and Form F-3) for potential equity issuance.
- Review the most recent Form 20-F or quarterly reports for actual financial performance data, as this 6-K does not include it.